Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Advanced biopsy-proven metastatic non-small cell lung cancer~* Somatic activating mutation in EGFR~* No prior treatment with an EGFR TKI~* No prior treatment with a VEGF inhibitor~* Measurable (RECIST 1.1) indicator lesion not previously irradiated~* Karnofsky performance status (KPS) ≥ 70%~* Age \>18 years old~* Adequate organ function~  * AST, ALT ≤ 3 x ULN~ * Total bilirubin ≤ 1.5x ULN~ * Creatinine ≤ 1.5x ULN OR calculated creatinine clearance \> 60ml/min~ * Absolute neutrophil count (ANC) ≥ 1000 cells/mm3~ * Hemoglobin≥8.0 g/dL~ * Platelets ≥100,000/mm3~Exclusion Criteria:~* Any contra-indications to bevacizumab which include but are not limited to recent~  1. Any previous venous thromboembolism \> NCI CTCAE Grade 3~ 2. Severe uncontrolled hypertension (systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥ 100mmHg)~ 3. Cardiovascular disease including stroke of myocardial infarction \<6 months prior to study enrollment, New York Heart Association Grade 2 or greater congestive heart failure, serious cardiac arrythmia uncontrolled by medication~ 4. Hemorrhagic brain metastases. Asymptomatic (not requiring escalating doses of steroids) brain metastases are acceptable.~ 5. History of severe proteinuria (urine dipstick ≥ 2+ or 24 hr urine \> 2gm/24hr)~ 6. Prior history of hypertensive crisis or hypertensive encephalopathy~ 7. History of a central nervous system disease (e.g. seizures) unrelated to cancer unless adequately treated with standard medical therapy~ 8. Significant vascular disease (e.g. aortic aneurysm requiring surgical repair)≥ 6 months prior to study enrollment~ 9. History of hemoptysis (≥1/2 teaspoon of bright red blood per episode) within the last 3 months~ 10. Evidence of a bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)~ 11. Current or recent (within 10 days of study drug start) use of aspirin (\>325mg daily), clopidogrel (\>75mg daily).~ 12. Recent initiation of full dose oral or parental anticoagulants that have not been in place for at least 2 weeks.~ 13. Tumor invading or abutting major blood vessels~ 14. Tumor histology classified by squamous cell histology.~ 15. Any history of abdominal fistula or GI perforation within 6 months of study enrollment~* Pregnant or lactating women~* Any type of systemic anticancer therapy (chemotherapy or experimental drugs) within 2 weeks of starting treatment on protocol~* Any radiotherapy within 1 week of starting treatment on protocol~* Any major surgery within 4 weeks of starting treatment on protocol~* Any evidence of clinically significant interstitial lung disease~* Known hypersensitivity to any component of bevacizumab and osimertinib

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- osimertinib and bevacizumab (Type: EXPERIMENTAL): Phase 1:~3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks~Phase 2:~Use MTD determined during phase 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete